Blog cardiovascular disease cholesterol Cholesterol Treatment Triallists Collaboration CVD Heart Disease Malcolm Kendrick obesity Oxford Rory Collins statins The Lancet



By Marika Sboros

When you assume strong proof of great well being dangers has dealt a terminal blow to the billion-dollar statin business’s coronary heart, assume again. Statins are still the world’s most prescribed drug and the drug business’s most profitable drugs ever.

In a brand new meta-analysis in The Lancet, UK scientists try CPR on the drug’s ailing status. They need docs to prescribe statins to more individuals over 75. They say that doing so will save 8000 lives annually. (That’s after some specialists calling for docs to place nearly everybody, including youngsters, on the medicine.) The authors also declare that statins produce “significant reductions in vascular events (heart attack and stroke) irrespective of age”.

Unbiased researchers say these are false claims and the research is riddled with terminal errors. Additionally they say the authors remain hopelessly conflicted with long-term hyperlinks with drug corporations.

Editors-in-chief of 24 major cardiovascular journals worldwide have joined the fray. In a co-ordinated defence of statins in an editorial in the Journal of the American Heart Association (JAHA), they “sound the alarm that human lives are at stake”. They are saying the danger is from  “medical misinformation” on statins that “travels faster through social networks than truth”.

‘Rogue’ voices

They say that dangers about statins are overhyped and resulting from “rogue” voices. “In many instances, celebrities, activists, and politicians convey false information”, they are saying. And never uncommonly, “authors with purely venal motives participate”.

Dr Zoe Harcombe

British public well being researcher Dr Zoë Harcombe sees issues by way of a very totally different, unbiased lens. Harcombe has accomplished intensive research into the cholesterol-lowering medicine. She once memorably referred to as them “one of the biggest crimes against humanity that the pharmaceutical industry has unleashed”.

In a rapid-response critique of The Lancet research, she identifies material errors and false claims. Amongst others, Harcombe hones in on the research’s primary suggestion of statins for those over 75.

She cites the “warnings and precautions” listing on the package deal insert of Lipitor, probably the most prescribed statin: “Speak to your doctor, pharmacist or nurse before taking Lipitor if ….  you are older than 70.”

Dr Malcolm Kendrick

Scottish MD Malcolm Kendrick says that The Lancet authors are hopelessly conflicted. And that it exhibits in their many false claims.

Kendrick has many years of medical expertise in remedy of CVD. He’s additionally writer of The Nice Ldl cholesterol Con: The Fact About What Really Causes Heart Disease and How To Keep away from it.

His latest guide due for release in June is A Statin Nation: Damaging Tens of millions in a Brave New Publish-health World.

Spoiler alert: Kendrick doesn’t consider that a deficiency of statins causes heart disease.

In a shortened version of his latest blog under, Kendrick stops just a little in need of saying that the researchers have made a pact with the satan. As an alternative, he says that they’ve made a pact with the drug business. (Scroll down for a full version.)

By Malcolm Kendrick

Primarily, (the authors of The Lancet research and JAHA editorial) feel that certain issues, comparable to prescribing statins, are so vitally essential that critics ought to be silenced. Maybe all these editors should attempt studying this:

‘Congress shall make no law respecting an establishment of religion or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the Government for a redress of grievances.’

Yes, the US founding fathers knew the very first thing tyrannies all the time wish to do is take away freedom of speech. From that, all else follows. In the event that they don’t get that message, they should all be pressured to learn 1984 by George Orwell.

“Freedom is the freedom to say that two plus two make four. If that is granted, all else follows.”

Getting back to The Lancet paper. What do I think of it? The first thing to note is ‘who done it’.

Properly, in fact, it was the Ldl cholesterol Remedy Trialists Collaboration (CTT) from Oxford. Run by Professor Sir Rory Collins and Professor Colin Baigent. They do every one of these meta-analyses on statins because they hold all the info. So, no-one else can really do them.

Pact with satan or drug corporations?

The CTT is on this hallowed place as a result of they made a pact with the dev… sorry …they made a pact with the pharmaceutical business to grasp all the info on statins from all the pharmaceutical corporations that manufacture statins and collate the info.

Prof Rory Collins

The CTT are very intently associated with the Oxford Medical Trials Service Unit (CTSU). The CTSU is run by, and has employed, most of those within the CTT. Collins and Baigent, and so forth.

The CTSU is a medical trials unit. Final time I appeared, it had obtained almost £300 million in funding from the pharmaceutical business for operating medical trials on numerous cholesterol decreasing drugs.

The CTT won’t let anyone else see the info they maintain. Including all the info on opposed events [side-effects] and critical antagonistic occasions. It’s stored utterly secret.

Anyway, my level right here is that the CTT is a horribly conflicted organisation that has been paid, immediately or not directly, a substantial amount of cash by the pharmaceutical business.

(Editor’s notice: Click on right here for the lengthy listing of conflicts of curiosity Kendrick provides for The Lancet authors. It’s a sobering learn.)

As to the research itself. I wrote this as a speedy response to an article Baignet wrote in The BMJ concerning the research: I want to ask Colin Baigent one question: … why did you name this research ‘Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials’?  (Click on right here for Kendrick’s full ‘rapid response’ in The BMJ.)

Hidden knowledge

Yes, they claimed to have carried out a meta-analysis of 28 research, but they might solely use knowledge from 14 to make their claims. The most important of which was the Heart Safety Research (HPS), carried out by, guess who, Rory Collins from the CTSU and CTT.

As for the actual knowledge, it is the traditional obfuscation, skirting as near the direct lie as attainable without crossing that line.

Click right here to learn: Really! Statins negative effects all in the mind?

I will take a look at one concern. The primary declare was that “statin therapy or a more intensive statin regimen produced a 21% (RR 0·79, 95% CI 0·77–0·81) proportional reduction in major vascular events per 1·0 mmol/L reduction in LDL cholesterol.”

A 21% reduction in major vascular events. That sounds terribly impressive. Nevertheless, in case you have read my ebook, Doctoring Knowledge,  you’ll know that what’s most essential here isn’t what is claimed, it is what is not stated.

Do you see any mention of general mortality here? No, you don’t. Which signifies that it didn’t change. Also, you could notice this wording: “reduction in major vascular events”.

What’s a serious vascular event? Properly, it’s mainly a non-fatal coronary heart attack or a non-fatal stroke. There are different CV (cardiovascular) events but they’re much less widespread.

Notice again, no mention of fatal CV events. If there had been a discount right here, (the researchers) would have trumpeted it from the rooftops. Which signifies that we now have no reduction in mortality and no reduction in deadly CV occasions.

When to worry

In fact, it is value stopping non-fatal coronary heart assaults and strokes as these may be extraordinarily damaging and harmful things. Nevertheless, there is something value mentioning here that I’ve not likely coated before: There are coronary heart assaults and coronary heart assaults, and strokes and strokes.

A coronary heart attack (myocardial infarction or MI) is usually a crushing near-death event. It will possibly depart the guts severely weakened and liable to trigger right into a fatal heart arrhythmia at any time. The patient may be left a cardiac cripple.

Click on here to read: Statins madness: Sir Rory Collins of Statinshire at the helm?

Alternatively, docs can diagnose a coronary heart attack by a marginal rise in cardiac enzymes with no signs at all and no residual problems. But, they may record both of these events, so utterly totally different of their influence, as a non-fatal heart assault, with precisely the identical weighting.

Equally, a stroke can depart the individual nearly paralysed down one aspect, incontinent, unable to talk, eat, or move. Or, it may be a half-hour strange sensation with slight facial weak spot that absolutely resolves. Again, docs will listing both these occasions with precisely the same weighting.

Statins at heart

That may be a drawback in itself, in that these trials record events of utterly totally different severity as being equal. It additionally leads into another drawback: Who will make the analysis of a light coronary heart assault or stroke – and on what grounds?

It’ll most certainly be a physician. And that doctor may have prior information of whether or not the affected person was on a statin – or placebo. Sure, I know, medical trials are presupposed to be double-blinded. Which signifies that neither the participant, nor the investigator, ought to know who’s taking the drug, or the placebo.

Nevertheless, in actuality, they each know full nicely.

I was at a meeting a while back the place one of many investigators for the PCKS-9 drug Repatha was speaking concerning the research. At one point he talked about that a trial participant advised him that he knew he was not taking the cholesterol-lowering agent. When questioned how he knew, he stated: “Because my cholesterol level is the same as it always was.”

He nonetheless needed to proceed on the trial because he thought he was doing a “good” factor and helping to maneuver drugs ahead – and suchlike. It might be thought-about churlish to level out that the only thing he was serving to to maneuver forward was the revenue margins for Amgen.

The truth is that when you will have a medicine that has a big effect, e.g. decreasing cholesterol by 40%, this can be a very troublesome to factor to hide from the patient or the physician. They will see the figures on a pc display in entrance of them.

Bias in research

And if you end up on a medical trial and also you enter hospital, the docs have to be advised you’re in a medical trial and what it is.

So, these double blinded studies on statins usually are not successfully, or even remotely, double-blinded. Which signifies that bias in medical decision-making is now an choice.

Was it a coronary heart attack, or not? Nicely, they’re on a statin, so in all probability not. Or, they are taking a placebo, so it in all probability is. Bias, the very thing you are attempting to take away has crept straight again in the aspect door.

One other situation with an occasion is that there are numerous differing types of medical occasion. Demise can be one – obviously. Breaking your leg one other. Kidney failure would also rely as one, as would a severe rash, or emergency admission to a hospital for almost any purpose.

So, when a research states, as this one does, ‘reduction in major vascular events’, my thoughts, as it’s now educated to do, thinks to itself: “ What about other events that happened to them? Were they also reduced, did they stay the same or did they go up?”

Because in the event you scale back main vascular occasions but other critical occasions go up, then you have got achieved exactly and precisely nothing.

This can be a variation on pushing individuals off cliffs to cease them dying of coronary heart assaults.


Results: ‘Pushing 100 people prevented all trial participants from suffering a fatal heart attack. We therefore recommend pushing everyone off a cliff to reduce the incidence of heart attacks in the general population.’ A.N. Fool et al.

Statins scale back main vascular events. [A major non-fatal vascular event could also be called as Serious Adverse Event (SAE)]. But do they scale back all critical antagonistic occasions (SEAs)? If not, you’re simply replacing a serious vascular occasion with one thing equally nasty?

Which leads on to the subsequent query, do we know from the statin trials if statins do scale back SAEs in complete? The reply is that we do not know this, for positive. That’s because the CTT has these knowledge, and refuses to let anybody else see them.

Nevertheless, Huge Brother has not censored some knowledge. The Cochrane collaboration (earlier than they began the sad slide to bias and corruption) looked at this problem – method again in 2003. They received as much knowledge as they might from the 5 main main prevention statin trials on the time.

What the analysis says

Right here was (The Cochrane Collaboration) conclusion on SAEs:

In the two trials where critical hostile events are reported, the 1.8% absolute discount in myocardial infarction and stroke ought to be mirrored by an analogous absolute reduction in complete critical antagonistic occasions; myocardial infarction and stroke are, by definition, critical antagonistic events. Nevertheless, this isn’t the case; critical antagonistic events are comparable within the statin group, 44.2%, and the control group, 43.9%.

This is in line with the likelihood that (statin remedy will increase) unrecognized critical antagonistic events and that the magnitude of the rise is just like the magnitude of the reduction in cardiovascular critical antagonistic occasions in these populations. This speculation needs to be examined by evaluation of complete critical hostile occasion knowledge in both previous and future statin trials.

Critical hostile occasion knowledge is obtainable to trial authors, drug corporations and drug regulators. The opposite measure of general impression, complete mortality, is on the market in all 5 trials and isn’t decreased by statin therapy.

What does this mean in reality? Properly, gathering it all together: Statins (in the over 75s) do not scale back mortality. They don’t forestall fatal MIs and strokes. Whereas they scale back critical cardiac events, beforehand revealed outcomes reveal they don’t scale back complete critical hostile occasions.

Which signifies that they’re, watch for it, absolutely and utterly useless.

Two plus two does equal 4. All the time bear that reality in mind.